Dr OJEDA-URIBE Mario

Fiche personne

Coordonnées

Hôpital Emile Muller
20 rue du Dr Laennec
68070 MULHOUSE Cedex

03 89 64 77 55

Territoire

Alsace

Statut

Hospitalier

Affiliation

Groupe hospitalier de la région de Mulhouse et Sud-Alsace (GHRMSA)

Publications

Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Neuman L, Joseph A, Bouzid R, Lescroart M, Mariotte E, Ederhy S, Tuffet S, Baudel JL, Benhamou Y, Galicier L, Grangé S, Provôt F, Neel A, Pène F, Delmas Y, Presne C, Poullin P, Wynckel A, Perez P, Barbet C, Halimi JM, Chatelet V, Rebibou JM, Ojeda-Uribe M, Vigneau C, Mesnard L, Veyradier A, Azoulay E, Coppo P, Chabriat H,

J Neurol. 2023 07 1;:

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.

Fenaux P, Gobbi M, Kropf P, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva-Kyuchukova LT, Demeter J, Griffiths EA, Yee KWL, Döhner K, Hao Y, Keer HN, Azab M, Döhner H

Blood Adv. 2023 06 5;:

A low lymphocyte-to-monocyte ratio (LMR) predicts PFS, POD24 and OS in previously untreated, high tumor burden follicular lymphoma (FL): an analysis from the RELEVANCE trial

Mozas P, Ammar RO, Chartier L, Nastoupil L, Bachy E, Bezsera SM, Barnes J, Bijou F, Goy A, Zerazhi H, Cartron G, Ojeda-Uribe M, Choquet S, Joly B, Cheminant M, García-Sancho AM, Eradat H, Gressin R, Abrisqueta P, Parcelier A, Salazar MJR, Bonnet C, Crump M, López-Guillermo A, Morschhauser F

Hematol Oncol. 2023 06;41 Suppl 2:290-291

Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France.

Dumas PY, Bertoli S, Bonmati C, Carre M, Lambert J, Ojeda-Uribe M, Chantepie S, Paul F, Jourdan E, Haiat S, Tavernier E, Peterlin P, Marolleau JP, Laribi K, Orvain C, Cabrera Q, Turlure P, Girault S, Balsat M, Bernard M, Bene MC, Pigneux A, Dombret H, Récher C

Leuk Res. 2022 06 20;120:106901

Prospective Comparison of Outcomes with Azacitidine and Decitabine in AML Patients Ineligible for Intensive Chemotherapy.

Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva LT, Demeter J, Griffiths EA, Yee KW, Issa JJ, Bewersdorf JP, Keer HN, Hao Y, Azab M, Döhner H

Blood. 2022 05 4;:

Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial.

Bouvier A, Hamel JF, Delaunay J, Delabesse E, Dumas PY, Ledoux MP, Peterlin P, Luquet I, Guepin GR, Bulabois CE, Hernanz MPG, Guillerm G, Guieze R, Hicheri Y, Simand C, Himberlin C, Hunault-Berger M, Bernard M, Jourdan E, Caillot D, Dorvaux V, Tavernier E, Daguindau E, Banos A, Ojeda-Uribe M, Gyan E, Magda A, Marolleau JP, Turlure P, Bouscary D, Humbrecht C, Zerazhi H, Christine Béné M, Pigneux A, Carre M, Ifrah N, Blanchet O, Vey N, Récher C, Cornillet-Lefèbvre P,

Eur J Haematol. 2021 Mar 25;:

Conventional chemotherapy for Acute Myeloid Leukemia in older adults: impact on nutritional, cognitive and functional status.

Jouzier C, Hamel JF, Dumas PY, Delaunay J, Bonmati C, Guièze R, Hunault M, Banos A, Lioure B, Béné MC, Ianotto JC, Ojeda-Uribe M, Paul F, Bernard M, Jourdan E, Zerazhi H, Vey N, Ifrah N, Recher C, Pigneux A, Cahn JY,

Eur J Haematol. 2021 Mar 18;:

Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.

Fodil S, Raffoux E, Dumas PY, Desbrosses Y, Larosa F, Chantepie S, Larcher MV, Mear JB, Peterlin P, Hunault-Berger M, Hospital MA, Morel V, Lucas N, Vidal V, Salanoubat C, Michel J, Mediavilla C, Ojeda-Uribe M, Alexis M, Frayfer J, Carré M, Maillard N, Redjoul R, Banos A, Detrait M, Cluzeau T, Wickenhauser S, Chaoui D, Elassy M, Pigneux A, Dombret H, Récher C, Bertoli S,

Leuk Lymphoma. 2021 Feb 17;:1-7

Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome.

Ojeda-Uribe M, Rimelen V, Marzullo C

J Blood Med. 2020 ;11:67-72

Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura.

Garraud O, Malot S, Herbrecht R, Ojeda-Uribe M, Lin JS, Veyradier A, Payrat JM, Liu K, Corash L, Coppo P

Transfus. Apher. Sci.. 2019 Nov 5;:102665

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C,

J. Clin. Oncol.. 2018 Sep 27;:JCO2018787366

Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura.

Herbrecht R, Ojeda-Uribe M, Kientz D, Fohrer C, Bohbot A, Hinschberger O, Liu KL, Remy E, Ernst C, Lin JS, Corash L, Cazenave JP

Vox Sang.. 2018 May 21;:

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.

Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, Bonmati C, Carré M, Couturier MA, Daguindau E, Marolleau JP, Orsini-Piocelle F, Delaunay J, Tavernier E, Lissandre S, Ojeda-Uribe M, Sanhes L, Sutton L, Banos A, Fornecker LM, Bernard M, Bouscary D, Saad A, Puyade M, Rouillé V, Luquet I, Béné MC, Hamel JF, Dreyfus F, Ifrah N, Pigneux A

Blood Cancer J. 2017 06 2;7(6):e568

Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre.

Grall M, Azoulay E, Galicier L, Provôt F, Wynckel A, Poullin P, Grange S, Halimi JM, Lautrette A, Delmas Y, Presne C, Hamidou M, Girault S, Pène F, Perez P, Kanouni T, Seguin A, Mousson C, Chauveau D, Ojeda-Uribe M, Barbay V, Veyradier A, Coppo P, Benhamou Y

Am. J. Hematol.. 2017 Apr;92(4):381-387

Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.

Cahu X, Carré M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hicheri Y, Guillerm G, Didier B, Larosa F, Ojeda-Uribe M, Bernard M, Bene MC, Ifrah N, Cahn JY

Eur. J. Haematol.. 2017 Jan;:

Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients.

Ojeda-Uribe M, Morel O, Ungureanu C, Desterke C, Le Bousse-Kerdilès MC, Boulahdour H

Cancer Med. 2016 09;5(9):2378-84

Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial.

Viallard JF, Agape P, Barlogis V, Cozon G, Faure C, Fouyssac F, Gaud C, Gourin MP, Hamidou M, Hoarau C, Husseini F, Ojeda-Uribe M, Pavic M, Pellier I, Perlat A, Schleinitz N, Slama B

BMC Immunol.. 2016 Sep;17(1):34

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G

Lancet. 2016 Jun 11;387(10036):2402-11

Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.

Ojeda-Uribe M, Merieau S, Guillon M, Aujoulat O, Hinschberger O, Eisenmann JC, Kenizou D, Debliquis A, Veyradier A, Chantrel F

J Oncol Pharm Pract. 2016 Apr;22(2):361-70

Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.

Fizesan M, Boin C, Aujoulat O, Newinger G, Ghergus D, Watier H, Lustig H, Ojeda-Uribe M

J Oncol Pharm Pract. 2016 Feb;22(1):188-92

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study.

Hunault-Berger M, Leguay T, Huguet F, Lepretre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Escoffre-Barbe M, Bories P, Himberlin C, Chevallier P, Rousselot P, Reman O, Boulland ML, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Lafage-Pochitaloff M, Bene MC, Liens D, Godfrin Y, Ifrah N, Dombret H

Am J Hematol. 2015 Sep;90(9):811-8

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.

Tardy MP, Gastaud L, Ojeda-Uribe M, Boscagli A, Caruso S, Skaf R, Gutnecht J, Thyss A, Peyrade F

Exp Hematol Oncol. 2015 ;4:18

Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia.

Recher C, Bene MC, Lioure B, Pigneux A, Vey N, Delaunay J, Luquet I, Hunault M, Guyotat D, Bouscary D, Fegueux N, Jourdan E, Lissandre S, Escoffre-Barbe M, Bonmati C, Randriamalala E, Guieze R, Ojeda-Uribe M, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Guardiola P

Leukemia. 2014 Feb;28(2):440-3

Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.

Grisouard J, Ojeda-Uribe M, Looser R, Hao-Shen H, Lundberg P, Duek A, Jeandidier E, Karow A, Skoda RC

Blood. 2013 Nov 21;122(22):3694-6

Intrathoracic extramedullary haematopoiesis: the advantages of hybrid imaging.

Moulin V, Ungureanu C, Ojeda-Uribe M, Thiebault S, Porot C, Angoue O, Boulahdour H

Diagn Interv Imaging. 2012 Nov;93(11):897-902

Therapy-related acute myeloid leukemia (t-AML) with poor-risk cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemia.

Ojeda-Uribe M, Schneider A, Luquet I, Berceanu A, Cornillet-Lefebvre P, Jeandidier E, Lioure B, Ades L, Mauvieux L, Himberlin C

Eur J Haematol. 2012 Sep;89(3):267-72

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.

Lioure B, Bene MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, Blaise D, Witz B, Delain M, Cornillon J, Luquet I, Blanchet O, Cornillet-Lefebvre P, Carre M, Hunault M, Larosa F, Lamy T, Randriamalala E, Ojeda-Uribe M, Berthou C, Fornecker L, Harousseau JL, Bouscary D, Ifrah N, Cahn JY

Blood. 2012 Mar 22;119(12):2943-8

Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities.

Perrot A, Luquet I, Pigneux A, Mugneret F, Delaunay J, Harousseau JL, Barin C, Cahn JY, Guardiola P, Himberlin C, Recher C, Vey N, Lioure B, Ojeda-Uribe M, Fegueux N, Berthou C, Randriamalala E, Bene MC, Ifrah N, Witz F

Blood. 2011 Jul 21;118(3):679-85

Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.

Ojeda-Uribe M, Caron C, Itzhar-Baikian N, Debliquis A

Am. J. Hematol.. 2010 May;85(5):396

Lessons from a case of oromandibular mucormycosis treated with surgery and a combination of amphotericin B lipid formulation plus caspofungin.

Ojeda-Uribe M, Herbrecht R, Kiefer MH, Schultz P, Chain J, Chenard MP, Servant JM, Debry C

Acta Haematol. 2010;124(2):98-102

Administration of rituximab during the first trimester of pregnancy without consequences for the newborn.

Ojeda-Uribe M, Gilliot C, Jung G, Drenou B, Brunot A

J Perinatol. 2006 Apr;26(4):252-5

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stephane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P

Leukemia. 2006 Mar;20(3):400-3.

Fiche personne Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques